A double-blind, placebo-controlled crossover trial of nadolol and verapamil in mild and moderately symptomatic hypertrophic cardiomyopathy
- 1 June 1993
- journal article
- clinical trial
- Published by Elsevier in Journal of the American College of Cardiology
- Vol. 21 (7) , 1672-1679
- https://doi.org/10.1016/0735-1097(93)90386-f
Abstract
No abstract availableKeywords
This publication has 34 references indexed in Scilit:
- Clinical Course and Prognosis of Hypertrophic Cardiomyopathy in an Outpatient PopulationNew England Journal of Medicine, 1989
- Hypertrophic CardiomyopathyNew England Journal of Medicine, 1987
- Hypertrophic CardiomyopathyNew England Journal of Medicine, 1987
- Modification of abnormal left ventricular diastolic properties by nifedipine in patients with hypertrophic cardiomyopathy.Circulation, 1982
- Nadolol: A New β-Adrenoceptor AntagonistNew England Journal of Medicine, 1981
- NadololDrugs, 1980
- Verapamil therapy: a new approach to the pharmacologic treatment of hypertrophic cardiomyopathy. II. Effects on exercise capacity and symptomatic status.Circulation, 1979
- Verapamil therapy: a new approach to the pharmacologic treatment of hypertrophic cardiomyopathy. I. Hemodynamic effects.Circulation, 1979
- Noninvasive assessment of clinical response to oral propranolol therapyThe American Journal of Cardiology, 1975
- Amelioration of Angina Pectoris in Idiopathic Hypertrophic Subaortic Stenosis with Beta-Adrenergic BlockadeCirculation, 1967